Overview

Oral Aripiprazole Open-Label Rollover Study

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to test the long-term safety and tolerability of oral aripiprazole in adolescent patients with schizophrenia.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Treatments:
Aripiprazole
Criteria
Inclusion Criteria:

- Subjects with a confirmed Axis I Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV) diagnosis of schizophrenia who must have completed
Otsuka study 31-03-241 (NCT00102518) treatment of adolescent subjects with
schizophrenia

Exclusion Criteria:

- Patients with a co-morbid serious, uncontrolled systemic illness

- Patients with a significant risk of committing suicide